Remifentanil Versus Rocuronium for Optimising Video Laryngoscopy Assisted Tracheal Intubation—The ROCVIDEO Trial Protocol
Study context
- Population
- Adults (ASA class I–III) undergoing GA with video laryngoscopy-assisted orotracheal intubationplanned
- Participants
- 2,684 adults
- Planned comparison
- Rocuronium vs Remifentanil
- Primary endpoint
- Co-primary: (I) anaesthesia-related adverse events and (II) failed first-pass intubation
Methodological detailsblinded, multicentre, Danish-Swedish, 1:1 randomisation, co-primary outcomes, Powered to detect 30% relative risk reduction (power 80% for failed first pass, 99% for adverse events), two-sided α 0.025, As of 15 June 2026, 707 participants randomised across 15 sites; recruitment expected complete third quarter of 2027
- Blinded
- Multicentre
- Danish-Swedish
- 1:1 randomisation
- Co-primary outcomes
- Powered to detect 30% relative risk reduction (power 80% for failed first pass, 99% for adverse events), two-sided α 0.025
- As of 15 June 2026, 707 participants randomised across 15 sites; recruitment expected complete third quarter of 2027
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Remifentanil Versus Rocuronium for Optimising Video Laryngoscopy Assisted Tracheal Intubation—The ROCVIDEO Trial Protocol. Acta Anaesthesiol Scand. Published 16 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →